Business Context and Reporting Period
Company: Maris-Tech Ltd. (MTEK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Maris-Tech is an Israeli B2B provider of AI-enabled video and edge computing technology, primarily serving defense, aerospace, and homeland security sectors. The company develops miniature, low-power video processing assemblies and OEM components for unmanned platforms and surveillance systems.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $1,341,218 | $6,078,953 |
| Cost of Revenues | $1,704,967 | $2,562,832 |
| Gross Profit (Loss) | $(363,749) | $3,516,121 |
| Operating Loss | $(5,224,425) | $(1,348,744) |
| Net Loss | $(5,409,322) | $(1,233,892) |
| Cash and Cash Equivalents (Dec 31) | $2,545,823 | $2,294,679 |
| Working Capital | $2,276,976 | $5,470,525 |
| Accumulated Deficit | $(17,545,337) | $(12,136,015) |
| Convertible Promissory Notes | $1,958,304 (Liability) | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by 78% ($4.74 million) compared to 2024. Management attributes this to a strategic shift toward selling complete systems, which have longer and more complex sales cycles than the OEM products that drove 2024 revenue.
- Gross Margin Erosion: The company moved from a gross profit of $3.52 million in 2024 to a gross loss of $363,749 in 2025. This was driven by lower sales volumes while fixed costs remained relatively stable.
- Increased Operating Loss: Operating loss widened by 287% to $5.22 million. While General and Administrative expenses decreased by 20%, Research and Development expenses increased by 38% due to the development of new full systems, and Sales and Marketing expenses rose by 26% due to expanded headcount and overseas exhibitions.
- Debt Financing: In November 2025, the company issued $2.0 million in convertible promissory notes. Additionally, the company drew $2.0 million on a new $4.0 million credit line facility.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern. Management believes its plans to improve liquidity (cost reductions, capital raises) alleviate this doubt for at least 12 months, but future profitability is not guaranteed.
- Backlog: As of May 14, 2026, backlog was approximately $3.1 million. Management notes that backlog is an uncertain indicator of future earnings as orders can be cancelled or deferred.
- Geopolitical Risks: Significant risks are associated with ongoing conflicts in Israel and the Middle East (Israel-Hamas, Israel-Hezbollah, Israel-Iran). These conflicts have led to the mobilization of reserve personnel (one employee called up as of May 2026) and potential supply chain disruptions.
- Capital Raises:
- March 2026: Completed a registered direct offering raising approximately $2.0 million (882,825 shares and pre-funded warrants).
- March 2026: Entered an "at-the-market" sales agreement to sell up to $3.0 million of ordinary shares.
- Israeli Innovation Authority (IIA) Grants: The company has contingent liabilities of approximately $655,000 (including interest) related to royalties on sales of products developed with IIA grants.
Investor Verification Checklist
- Liquidity Runway: Verify if the $2.6 million cash balance and recent $2.0 million raise are sufficient to cover the $5.4 million annual burn rate without further dilution.
- Revenue Recognition Timing: Assess the validity and timing of the $3.1 million backlog, given the history of order cancellations and the shift to longer-cycle system sales.
- Geopolitical Exposure: Evaluate the impact of ongoing Israeli military conflicts on the company's ability to manufacture, ship, and retain key R&D personnel.
- Dilution Risk: Review the terms of the $2.0 million convertible notes (conversion at 70% of VWAP) and the recent equity offering to understand potential dilution to existing shareholders.
- IIA Obligations: Confirm the status of royalty payments owed to the Israeli Innovation Authority and any restrictions on transferring manufacturing or know-how outside of Israel.